View in EDS

Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Authors: Cárdenas V; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: cardenasv@yahoo.com., Le Gars M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Mathieu.legars1@gmail.com., Truyers C; Janssen Research & Development, Beerse Belgium. Electronic address: ctruyers@its.jnj.com., Ruiz-Guiñazú J; Janssen Research & Development, Beerse Belgium. Electronic address: JRuizGui@its.jnj.com., Struyf F; Janssen Research & Development, Beerse Belgium. Electronic address: fstruyf@gmail.com., Colfer A; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: acolfer@its.jnj.com., Bonten M; Julius Center for Health Services and Primary Care, UMC Utrecht, Utrecht University and European Clinical Alliance on Infectious Diseases, Utrecht, the Netherlands. Electronic address: m.j.m.bonten@umcutrecht.nl., Borobia A; Clinical Pharmacology Department, La Paz University Hospital. School of Medicine, Universidad Autónoma de Madrid, IdiPAZ. CIBERINFECT, Spain. Electronic address: alberto.borobia@salud.madrid.org., Reisinger EC; Rostock University Medical Center, Dept. of Infectious Diseases and Tropical Medicine, Rostock, Germany. Electronic address: emil.reisinger@uni-rostock.de., Kamerling IMC; Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, the Netherlands. Electronic address: idvisser@chdr.nl., Douoguih M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: macaya.douoguih@merck.com., Sadoff J; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Jerry@Centivax.com.
Source: Vaccine [Vaccine] 2024 Jun 11; Vol. 42 (16), pp. 3536-3546. Date of Electronic Publication: 2024 May 04.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38705804
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cárdenas+V%22">Cárdenas V</searchLink>; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: cardenasv@yahoo.com.<br /><searchLink fieldCode="AU" term="%22Le+Gars+M%22">Le Gars M</searchLink>; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Mathieu.legars1@gmail.com.<br /><searchLink fieldCode="AU" term="%22Truyers+C%22">Truyers C</searchLink>; Janssen Research & Development, Beerse Belgium. Electronic address: ctruyers@its.jnj.com.<br /><searchLink fieldCode="AU" term="%22Ruiz-Guiñazú+J%22">Ruiz-Guiñazú J</searchLink>; Janssen Research & Development, Beerse Belgium. Electronic address: JRuizGui@its.jnj.com.<br /><searchLink fieldCode="AU" term="%22Struyf+F%22">Struyf F</searchLink>; Janssen Research & Development, Beerse Belgium. Electronic address: fstruyf@gmail.com.<br /><searchLink fieldCode="AU" term="%22Colfer+A%22">Colfer A</searchLink>; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: acolfer@its.jnj.com.<br /><searchLink fieldCode="AU" term="%22Bonten+M%22">Bonten M</searchLink>; Julius Center for Health Services and Primary Care, UMC Utrecht, Utrecht University and European Clinical Alliance on Infectious Diseases, Utrecht, the Netherlands. Electronic address: m.j.m.bonten@umcutrecht.nl.<br /><searchLink fieldCode="AU" term="%22Borobia+A%22">Borobia A</searchLink>; Clinical Pharmacology Department, La Paz University Hospital. School of Medicine, Universidad Autónoma de Madrid, IdiPAZ. CIBERINFECT, Spain. Electronic address: alberto.borobia@salud.madrid.org.<br /><searchLink fieldCode="AU" term="%22Reisinger+EC%22">Reisinger EC</searchLink>; Rostock University Medical Center, Dept. of Infectious Diseases and Tropical Medicine, Rostock, Germany. Electronic address: emil.reisinger@uni-rostock.de.<br /><searchLink fieldCode="AU" term="%22Kamerling+IMC%22">Kamerling IMC</searchLink>; Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, the Netherlands. Electronic address: idvisser@chdr.nl.<br /><searchLink fieldCode="AU" term="%22Douoguih+M%22">Douoguih M</searchLink>; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: macaya.douoguih@merck.com.<br /><searchLink fieldCode="AU" term="%22Sadoff+J%22">Sadoff J</searchLink>; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Jerry@Centivax.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2024 Jun 11; Vol. 42 (16), pp. 3536-3546. <i>Date of Electronic Publication: </i>2024 May 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38705804
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2024.04.059
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3536
    Titles:
      – TitleFull: Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cárdenas V
      – PersonEntity:
          Name:
            NameFull: Le Gars M
      – PersonEntity:
          Name:
            NameFull: Truyers C
      – PersonEntity:
          Name:
            NameFull: Ruiz-Guiñazú J
      – PersonEntity:
          Name:
            NameFull: Struyf F
      – PersonEntity:
          Name:
            NameFull: Colfer A
      – PersonEntity:
          Name:
            NameFull: Bonten M
      – PersonEntity:
          Name:
            NameFull: Borobia A
      – PersonEntity:
          Name:
            NameFull: Reisinger EC
      – PersonEntity:
          Name:
            NameFull: Kamerling IMC
      – PersonEntity:
          Name:
            NameFull: Douoguih M
      – PersonEntity:
          Name:
            NameFull: Sadoff J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 06
              Text: 2024 Jun 11
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 16
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1